Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 100,000 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 100,000 shares of the stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $75.74, for a total value of $7,574,000.00. Following the completion of the transaction, the director directly owned 880,073 shares in the company, valued at $66,656,729.02. This trade represents a 10.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Liquidia Stock Up 2.0%

Liquidia stock traded up $1.50 during midday trading on Wednesday, reaching $75.54. The company’s stock had a trading volume of 2,085,398 shares, compared to its average volume of 1,848,579. The company has a market cap of $6.72 billion, a P/E ratio of 539.61 and a beta of 0.58. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The business has a 50-day simple moving average of $54.51 and a 200-day simple moving average of $42.91. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $77.09.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. The firm’s quarterly revenue was up 4187.1% on a year-over-year basis. On average, research analysts expect that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on LQDA. BTIG Research upped their price target on Liquidia from $59.00 to $109.00 and gave the company a “buy” rating in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Needham & Company LLC boosted their price objective on shares of Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $68.00 target price on shares of Liquidia in a research report on Thursday, June 4th. Three analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Liquidia currently has a consensus rating of “Moderate Buy” and an average target price of $67.43.

Institutional Investors Weigh In On Liquidia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Liquidia during the fourth quarter worth approximately $25,000. NewEdge Advisors LLC acquired a new position in shares of Liquidia in the 2nd quarter valued at $25,000. FNY Investment Advisers LLC purchased a new stake in Liquidia in the 3rd quarter valued at $34,000. Covestor Ltd raised its position in Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in Liquidia by 281.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after purchasing an additional 4,927 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).